Firdapse amifampridine: Phase III started

Catalyst began a double-blind, placebo-controlled, crossover, U.S. Phase III trial to evaluate 20-80 mg oral Firdapse given 2-4 times a day in 7-day treatment periods in about 10 patients ages 2-17. Patients will receive Firdapse in an open-label run-in period for up to 4 weeks until a stable dose and frequency of Firdapse is achieved for 7 days. ...